Given the current public health crisis, and in order to prepare for its financial consequences, Quantum Genomics has secured new financing thanks to an agreement with Negma Group Ltd, dated March 26, 2020. Read the press release
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the appointment of Benoît Gueugnon as Vice-President Finance. He will succeed Marc Karako who is leaving the Company. Read the…
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced it will share preclinical results of firibastat in heart failure post myocardial ischemia during an oral presentation at the Gordon Research Conference…
Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced the initiation of its pivotal Phase III FRESH…